Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E7.10 EPS (ttm)9.94 Insider Own0.30% Shs Outstand1.31B Perf Week0.93%
Market Cap92.12B Forward P/E8.88 EPS next Y7.94 Insider Trans-15.82% Shs Float1.30B Perf Month-1.01%
Income13.50B PEG- EPS next Q2.26 Inst Own77.30% Short Float0.98% Perf Quarter-5.77%
Sales30.39B P/S3.03 EPS this Y-16.50% Inst Trans0.15% Short Ratio1.19 Perf Half Y-10.86%
Book/sh14.71 P/B4.79 EPS next Y-7.33% ROA25.60% Target Price81.58 Perf Year-18.13%
Cash/sh- P/C- EPS next 5Y-4.81% ROE82.90% 52W Range65.38 - 101.25 Perf YTD-1.55%
Dividend2.08 P/FCF- EPS past 5Y41.20% ROI72.40% 52W High-30.37% Beta1.15
Dividend %2.95% Quick Ratio4.00 Sales past 5Y29.40% Gross Margin86.00% 52W Low7.83% ATR1.38
Employees8000 Current Ratio4.20 Sales Q/Q-13.90% Oper. Margin58.00% RSI (14)50.81 Volatility1.48% 1.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.50% Profit Margin44.40% Rel Volume0.59 Prev Close69.94
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 AMC Payout18.30% Avg Volume10.77M Price70.50
Recom2.30 SMA200.75% SMA50-2.17% SMA200-8.55% Volume6,338,988 Change0.80%
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-27-17 04:26PM  GILEAD SCIENCES INC Files SEC form 10-K, Annual Report
01:21PM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. at Motley Fool
11:22AM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development
08:05AM  Merck Restates 2016 Earnings, Takes $2.9B Charge at Investopedia
07:57AM  These 3 Big Pharma Stocks Are Ridiculously Cheap at Motley Fool
07:37AM  Why Vertex Expects Its Profit Margin to Rise in 2017
06:00AM  Drugmakers Eye $35B Market Amid Obesity Crisis at Investopedia
Feb-24-17 04:14PM  Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink
01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
11:11AM  Ten Stocks That Still Look Cheap at Barrons.com
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
09:20AM  7 Ultra-Cheap Value Stocks to Buy Now at Kiplinger
07:37AM  Gilead Sciences Expects a Fall in Its HCV Product Sales in 2017
Feb-23-17 05:06PM  AbbVie Stronger Bet Than Gilead, Amgen At Least Until 2020: Leerink
02:25PM  Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C at Insider Monkey
01:57PM  Baby Boomers: Gileads New Hep C Target Group at Investopedia
11:27AM  3 Beaten-Up Dividend Stocks: Are They Bargains? at Motley Fool
10:38AM  This Strategy Could Boost GILDs HIV Franchise Revenue in 2017
09:38AM  These Regimens Are Expected to See Solid Global Demand in 2017
08:00AM  Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs
07:52AM  Solid Uptake of This Drug Could Drive Gileads 2017 Product Sales
Feb-22-17 07:29PM  Cramer: Why Gilead could be a value trap at CNBC
06:21PM  Who Could Buy Bristol-Myers Squibb? at Motley Fool
05:27PM  Gilead Sciences Raises Dividend by Double Digits
04:31PM  Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs
03:53PM  3 Things Gilead Sciences' CEO Just Said That You'll Want to Know at Motley Fool
03:05PM  Gilead Sciences Expects to Witness an Earnings Fall in 2017
01:35PM  Gilead Sciences Expects to See a Revenue Fall in 2017
12:42PM  Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments at Barrons.com
12:21PM  Genmab and J&J's cancer drug set for blockbuster sales this year
11:40AM  What Are Analysts Recommendations for Gilead Sciences in 2017?
11:36AM  Ontario Becomes First Province To List EPCLUSA On Public Drug Plan To Treat All Six Genotypes Of Chronic Hepatitis C Infection CNW Group
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
12:45AM  [$$] Gilead Goes to the Head of the Line at The Wall Street Journal
Feb-21-17 04:48PM  Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
02:00PM  Did Gilead's new tool for speeding drug approval come at bargain-basement price? at bizjournals.com
01:04PM  [$$] Gilead Goes to the Head of the Line at The Wall Street Journal
11:03AM  Sarepta Sells Priority Review Voucher for $125M at Investopedia
10:05AM  Sarepta sells FDA review voucher for $125M, but analyst questions price at bizjournals.com
Feb-20-17 11:50AM  Gilead Sells Anti-Addiction Drug to Amygdala at Investopedia
10:00AM  Your Burning Biotech Questions Answered
09:57AM  Why Gilead Sciences Is a Buy at Motley Fool
Feb-18-17 05:41PM  Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc. at Motley Fool
08:23AM  Investors Are Betting Big Against Intercept Pharmaceuticals. Are They Wrong? at Motley Fool
Feb-17-17 08:49PM  Why President Trump Should Buy Gilead Sciences at Motley Fool
Feb-16-17 11:29AM  Gilead Receives Approval in Canada for ODEFSEY for the Treatment of HIV-1 Infection CNW Group
09:42AM  Why It's a Colossal Mistake to Sell Gilead Sciences Stock Now at Motley Fool
Feb-15-17 07:34PM  3 Stocks We're Watching in the First Quarter at Motley Fool
06:35PM  Cramer fires back at naysayers: Here's your proof that th...
06:22PM  Cramer fires back at naysayers: Here's your proof that this rally is real at CNBC
05:59PM  Proof the rally is real
04:29PM  Under the Microscope: Gilead's Recent Dividend Increase
12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at Barrons.com
12:01PM  Gileads HIV Drug Reports Positive Trial Data at Investopedia
11:04AM  Gilead Sciences (GILD) Value Trap
09:44AM  Gilead Sciences: Its Game to Lose? at Barrons.com
09:30AM  9 Top Pharmaceutical Stocks to Buy for the Dividends at Kiplinger
08:47AM  Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)
08:23AM  4 Stocks to Buy Near 52-Week Lows at Motley Fool
Feb-14-17 07:00PM  Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults Business Wire
04:32PM  ETFs with exposure to Gilead Sciences, Inc. : February 14, 2017
04:19PM  Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet
04:18PM  Gilead (GILD) Announces Data on Combination Therapy for HIV
03:33PM  Bristol-Myers Squibb: Takeover Target? at Barrons.com
12:53PM  Why I Just Bought More Shares of Gilead Sciences, Inc. at Motley Fool
11:17AM  Gilead Sciences: Not Out of the Woods Yet? at Barrons.com
10:39AM  Consider Gilead Sciences
10:19AM  No Bottoming Signs Yet for Gilead
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
09:25AM  The new multibillion-dollar HIV challenge no one is talking about at CNBC
08:23AM  Gilead Has 'Good News' But is it Enough? at TheStreet
07:56AM  Early movers: HUM, AET, GM, PLKI, DISCA, GNRC, ITT & more at CNBC
03:59AM  Better Buy: Illumina or Gilead Sciences? at Motley Fool
03:47AM  Gilead challenges GSK with strong HIV drug data
Feb-13-17 08:40PM  Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference
06:45PM  Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV Business Wire
06:45PM  Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors Business Wire
04:25PM  Can Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry?
12:14PM  Is Gilead Sciences Getting Ready for a Massive Acquisition? at Motley Fool
11:11AM  Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-12-17 01:32PM  Gilead Sciences, Fossil Reach 3-Year Low Prices
Feb-10-17 04:10PM  Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split
10:17AM  Why Gilead's Disastrous Forecast is Good News for Biotech at Barrons.com
09:55AM  Major Biotechs Scare Off Loads of Short Sellers
06:01AM  These 5 Stocks Are Showing Red Flags in February
Feb-09-17 04:04PM  Vista Outdoor, Fossil Group Dive into Thursdays 52-Week Low Club
02:50PM  Are cures bad for business?
02:49PM  Gilead's catch-22 on Hep C cure
01:03PM  Gilead Sciences, Inc. :GILD-US: Earnings Analysis: 2016 By the Numbers : February 9, 2017
12:58PM  Gilead to Battle GlaxoSmithKline for HIV Cure at Investopedia
11:14AM  Don't Panic: Gilead Sciences Really Isn't a Value Trap at Motley Fool
10:07AM  Gilead Slashes Sales Projection and Stock Tumbles at Investopedia
09:39AM  Gilead Sciences: Dead Money? at Barrons.com
09:30AM  Today's Research Reports on Gilead Sciences and Allergan Post Earnings Accesswire
12:10AM  [$$] Gileads Boom Fades and Bust Will Linger at The Wall Street Journal
Feb-08-17 05:45PM  Gilead tanks on weak forecast -8.61%
05:00PM  Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22 Business Wire
04:55PM  Why Gilead Sciences, Zillow Group, and Parsley Energy Slumped Today at Motley Fool
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM